Diphtheria is an infection caused by the bacterium Corynebacterium diphtheriae. Diphtheria causes a thick covering in the back of the throat. It can lead to difficulty breathing, heart failure, paralysis, and even death. CDC recommends vaccines for infants, children, teens and adults to prevent diphtheria. The presentation consists of basic concepts regarding the bacteria and its infection. It has explanation in detail about signs and symptoms of Diptheria
Diphtheria is an infection caused by the bacterium Corynebacterium diphtheriae. Diphtheria causes a thick covering in the back of the throat. It can lead to difficulty breathing, heart failure, paralysis, and even death. CDC recommends vaccines for infants, children, teens and adults to prevent diphtheria. The presentation consists of basic concepts regarding the bacteria and its infection. It has explanation in detail about signs and symptoms of Diptheria
Professional air quality monitoring systems provide immediate, on-site data for analysis, compliance, and decision-making.
Monitor common gases, weather parameters, particulates.
Nutraceutical market, scope and growth: Herbal drug technologyLokesh Patil
As consumer awareness of health and wellness rises, the nutraceutical market—which includes goods like functional meals, drinks, and dietary supplements that provide health advantages beyond basic nutrition—is growing significantly. As healthcare expenses rise, the population ages, and people want natural and preventative health solutions more and more, this industry is increasing quickly. Further driving market expansion are product formulation innovations and the use of cutting-edge technology for customized nutrition. With its worldwide reach, the nutraceutical industry is expected to keep growing and provide significant chances for research and investment in a number of categories, including vitamins, minerals, probiotics, and herbal supplements.
Introduction:
RNA interference (RNAi) or Post-Transcriptional Gene Silencing (PTGS) is an important biological process for modulating eukaryotic gene expression.
It is highly conserved process of posttranscriptional gene silencing by which double stranded RNA (dsRNA) causes sequence-specific degradation of mRNA sequences.
dsRNA-induced gene silencing (RNAi) is reported in a wide range of eukaryotes ranging from worms, insects, mammals and plants.
This process mediates resistance to both endogenous parasitic and exogenous pathogenic nucleic acids, and regulates the expression of protein-coding genes.
What are small ncRNAs?
micro RNA (miRNA)
short interfering RNA (siRNA)
Properties of small non-coding RNA:
Involved in silencing mRNA transcripts.
Called “small” because they are usually only about 21-24 nucleotides long.
Synthesized by first cutting up longer precursor sequences (like the 61nt one that Lee discovered).
Silence an mRNA by base pairing with some sequence on the mRNA.
Discovery of siRNA?
The first small RNA:
In 1993 Rosalind Lee (Victor Ambros lab) was studying a non- coding gene in C. elegans, lin-4, that was involved in silencing of another gene, lin-14, at the appropriate time in the
development of the worm C. elegans.
Two small transcripts of lin-4 (22nt and 61nt) were found to be complementary to a sequence in the 3' UTR of lin-14.
Because lin-4 encoded no protein, she deduced that it must be these transcripts that are causing the silencing by RNA-RNA interactions.
Types of RNAi ( non coding RNA)
MiRNA
Length (23-25 nt)
Trans acting
Binds with target MRNA in mismatch
Translation inhibition
Si RNA
Length 21 nt.
Cis acting
Bind with target Mrna in perfect complementary sequence
Piwi-RNA
Length ; 25 to 36 nt.
Expressed in Germ Cells
Regulates trnasposomes activity
MECHANISM OF RNAI:
First the double-stranded RNA teams up with a protein complex named Dicer, which cuts the long RNA into short pieces.
Then another protein complex called RISC (RNA-induced silencing complex) discards one of the two RNA strands.
The RISC-docked, single-stranded RNA then pairs with the homologous mRNA and destroys it.
THE RISC COMPLEX:
RISC is large(>500kD) RNA multi- protein Binding complex which triggers MRNA degradation in response to MRNA
Unwinding of double stranded Si RNA by ATP independent Helicase
Active component of RISC is Ago proteins( ENDONUCLEASE) which cleave target MRNA.
DICER: endonuclease (RNase Family III)
Argonaute: Central Component of the RNA-Induced Silencing Complex (RISC)
One strand of the dsRNA produced by Dicer is retained in the RISC complex in association with Argonaute
ARGONAUTE PROTEIN :
1.PAZ(PIWI/Argonaute/ Zwille)- Recognition of target MRNA
2.PIWI (p-element induced wimpy Testis)- breaks Phosphodiester bond of mRNA.)RNAse H activity.
MiRNA:
The Double-stranded RNAs are naturally produced in eukaryotic cells during development, and they have a key role in regulating gene expression .
The increased availability of biomedical data, particularly in the public domain, offers the opportunity to better understand human health and to develop effective therapeutics for a wide range of unmet medical needs. However, data scientists remain stymied by the fact that data remain hard to find and to productively reuse because data and their metadata i) are wholly inaccessible, ii) are in non-standard or incompatible representations, iii) do not conform to community standards, and iv) have unclear or highly restricted terms and conditions that preclude legitimate reuse. These limitations require a rethink on data can be made machine and AI-ready - the key motivation behind the FAIR Guiding Principles. Concurrently, while recent efforts have explored the use of deep learning to fuse disparate data into predictive models for a wide range of biomedical applications, these models often fail even when the correct answer is already known, and fail to explain individual predictions in terms that data scientists can appreciate. These limitations suggest that new methods to produce practical artificial intelligence are still needed.
In this talk, I will discuss our work in (1) building an integrative knowledge infrastructure to prepare FAIR and "AI-ready" data and services along with (2) neurosymbolic AI methods to improve the quality of predictions and to generate plausible explanations. Attention is given to standards, platforms, and methods to wrangle knowledge into simple, but effective semantic and latent representations, and to make these available into standards-compliant and discoverable interfaces that can be used in model building, validation, and explanation. Our work, and those of others in the field, creates a baseline for building trustworthy and easy to deploy AI models in biomedicine.
Bio
Dr. Michel Dumontier is the Distinguished Professor of Data Science at Maastricht University, founder and executive director of the Institute of Data Science, and co-founder of the FAIR (Findable, Accessible, Interoperable and Reusable) data principles. His research explores socio-technological approaches for responsible discovery science, which includes collaborative multi-modal knowledge graphs, privacy-preserving distributed data mining, and AI methods for drug discovery and personalized medicine. His work is supported through the Dutch National Research Agenda, the Netherlands Organisation for Scientific Research, Horizon Europe, the European Open Science Cloud, the US National Institutes of Health, and a Marie-Curie Innovative Training Network. He is the editor-in-chief for the journal Data Science and is internationally recognized for his contributions in bioinformatics, biomedical informatics, and semantic technologies including ontologies and linked data.
Multi-source connectivity as the driver of solar wind variability in the heli...Sérgio Sacani
The ambient solar wind that flls the heliosphere originates from multiple
sources in the solar corona and is highly structured. It is often described
as high-speed, relatively homogeneous, plasma streams from coronal
holes and slow-speed, highly variable, streams whose source regions are
under debate. A key goal of ESA/NASA’s Solar Orbiter mission is to identify
solar wind sources and understand what drives the complexity seen in the
heliosphere. By combining magnetic feld modelling and spectroscopic
techniques with high-resolution observations and measurements, we show
that the solar wind variability detected in situ by Solar Orbiter in March
2022 is driven by spatio-temporal changes in the magnetic connectivity to
multiple sources in the solar atmosphere. The magnetic feld footpoints
connected to the spacecraft moved from the boundaries of a coronal hole
to one active region (12961) and then across to another region (12957). This
is refected in the in situ measurements, which show the transition from fast
to highly Alfvénic then to slow solar wind that is disrupted by the arrival of
a coronal mass ejection. Our results describe solar wind variability at 0.5 au
but are applicable to near-Earth observatories.
Seminar of U.V. Spectroscopy by SAMIR PANDASAMIR PANDA
Spectroscopy is a branch of science dealing the study of interaction of electromagnetic radiation with matter.
Ultraviolet-visible spectroscopy refers to absorption spectroscopy or reflect spectroscopy in the UV-VIS spectral region.
Ultraviolet-visible spectroscopy is an analytical method that can measure the amount of light received by the analyte.
Observation of Io’s Resurfacing via Plume Deposition Using Ground-based Adapt...Sérgio Sacani
Since volcanic activity was first discovered on Io from Voyager images in 1979, changes
on Io’s surface have been monitored from both spacecraft and ground-based telescopes.
Here, we present the highest spatial resolution images of Io ever obtained from a groundbased telescope. These images, acquired by the SHARK-VIS instrument on the Large
Binocular Telescope, show evidence of a major resurfacing event on Io’s trailing hemisphere. When compared to the most recent spacecraft images, the SHARK-VIS images
show that a plume deposit from a powerful eruption at Pillan Patera has covered part
of the long-lived Pele plume deposit. Although this type of resurfacing event may be common on Io, few have been detected due to the rarity of spacecraft visits and the previously low spatial resolution available from Earth-based telescopes. The SHARK-VIS instrument ushers in a new era of high resolution imaging of Io’s surface using adaptive
optics at visible wavelengths.
2. •It is the chronic inflammation of the
interstitial tissues.
It is caused by:
(1) Viral infection.
(2) Infestation with lung worm.
(3) Secondary to lobar and lobular
pneumonia when the exudate becomes
organized.
(4) Secondary to some specific disease
e.g. Tuberculosis, Contagious bovine
pleuropneumonia in cattle.
3.
4. Clinical findings:
(1) Severe mixed dyspnoea.
(2) Easily induced cough.
(3) Slight rise o f temperature (it is very high in
infectious diseases).
(4) On percussion, dullness is heard on the anterior
and posterior borders of the lungs.
(5) On auscultation, week or absence of vesicular
sound but rales may be heard.
(6) Consolidation and fibrosis of the lung will cause
reduction in the respiratory surface, the lung will
loose some of its power of expansion as well as
some of its elasticity and this lead to death from
asphyxia.
5. Pneumonia in pet animals
Acute and chronic inflammatory
changes of the lungs and bronchi
characterized by respiratory
disturbances and complicated by
systemic effects of toxins
absorbed from the involved area.
6.
7. Causes:
(1) Primary viral involvement of the respiratory
tract followed -by secondary bacterial
invasion: e.g. Feline respiratory complex,
Canine distemper, Infectious tracheobronchitis
and Canine and Feline herpes virus.
(2) Classical pneumonia is due to bacterial
invasion.
(3) Parasitic invasion o f the bronchi as by
filaroides Aelurostronglus.
(4) Protozoan involvement, usually caused by
Toxoplasma.
8. (5) Mycotic bronchopneumonia may
result from Aspergillus or Histoplasma.
(6) Injury to the bronchial mucosa and
the inhalation or aspiration o f irritant
materials may cause pneumonia
directly and predispose the tissues to
secondary bacterial invasion.
NB: Any interference with immune
protective mechanisms may
predispose to pneumonia.
9.
10. Clinical findings:
(1)Drowsiness (lethargy).
(2) Anorexia.
(3) Deep cough o f low amplitude.
(4) Nasal ocular discharge.
(5) Progressive dyspnea.
(6) Increased body temperature.
(7) Blowing of the lips and cyanosis.
(8) Auscultation of the thorax usually reveals
consolidation.
(9) Complication such as pleuritis may occur.
11. Course o f the
Pneumonia:
(1) Lobar pneumonia: 7-10
days in horse, 3 weeks in
cattle
(2) Bronchopneumonia:
3-4 weeks in both.
12. Death may occurs in pneumonia from:
(1)Anoxia and respiratory failure.
(2)Heart failure
(3) Pleurisy.
(4) Pericarditis.
(5) Gangrenous pneumonia.
Clinical pathology:
(1) Respiratory secretion, exudates, nasal swabs,
tracheobronchial aspirates and bronchoalveolar lavage
samples can be submitted for isolation of viruses, bacteria,
fungi, cytological examination and determination of
antimicrobial sensitivity.
(2) Thoracentesis: when pleural effusion is suspected, to
obtain pleural fluid for analysis.
13. (3) Hematology: hematological
examination can be done if the infection is
bacterial or viral in nature and its severity.
1- PCV elevated in severely toxemic
animals which aren’t drinking water.
2- Severe bacterial bronchopneumonia and
pleuritis is charactrized by marked increase
in leukocytic count (leukocytosis).
3- Serum fibrinogen concentrations are
markedly elevated in horses with
pleuropneumonia and pleuritis.
14. (4) Fecal samples: for the detection of the
larvae when lungworm pneumonia is
suspected.
(5) Medical imaging: thoracic radiography and
ultrasonography.
(6) Respiratory function tests e.g. blood
gases and acid base balance tests.
(7) Necropsy: Necropsy o f selected early
cases will often assist in making a diagnosis
in outbreaks o f respiratory disease.
15. Diagnosis o f pneumonia
depends on:
(1) History.
(2) Clinical symptoms (Polypnea
in the early stages, dyspnea in
late stage, abnormal lung
sounds, cough, fever and
toxemia in bacterial pneumonia).
(3) Clinical pathology.
16. Differential diagnosis:
(1) Polypnea and dyspnea may result from
involvement of other body systems disturbances e.g.
1- Congestive heart failure.
2- Poisoning by histotoxic agents e.g. hydrocyanic acid.
3- Hyperthermia.
4- Acidosis.
The previous diseases are accompanied by respiratory
embarrassments but not by abnormal respiratory sounds,
which present in pulmonary involvement.
17. (2) Pleuritis is characterized by:
1) Shallow, abdominal type of respiration.
2) Friction sounds in the early stage and muffling lung
sounds. Fluid line detected by auscultation and
percussion in late stage.
•
(3) Pneumothorax is characterized by:
1) Inspiratory dyspnea.
2) An absence of vesicular sounds.
3) Bronchial sounds are audible over the base of the lung.
4) Hyperresonant sound on percussion.
18. (4) Contagious Bovine Pleuro-
pneumonia:
!It is a highly infectious septicemic
disease caused by mycoplasma
mycoides characterized by localization
in the lungs and pleura resulting to
acute lobar pneumonia and pleurisy.
!It occurs commonly in cattle and it is
characterized by high morbidity and
mortality rates.
19.
20. •Treatment of
pneumonia
(1) Avoid overcrowding and put the animal in worm dry
place free from air current and apply chest rug.
(2) Correct anaemia if present.
(3) Oxygen therapy if cyanosis is severe.
(4) Feed animal with easily digestible and palatable food
(green laxature food for ruminants, bran mash for
equines).
(5) Injection of vitamin C and A to increase body immunity.
21. (6) Expectorant e.g. Bisolvone (mucolytic and expectorant)
or trisolven (mucolytic, expectorant and bronchodilator) 1
ml/50 KgBW, IM, daily till recovery.
(7) Bronchodilators: to improves ventilation and tends to
correct oxygen exchange e.g. Aminophylline and
theophylline I.V. injection.
(8) Glucose 5-10%, 500 ml and saline solution 0.9%, 500
ml (or more) daily to control dehydration.
(9) Diuretics: e.g. pot. acetate and pot. citrate 15 gm from
each are added to the drinking water o f the animal every
day.
22. (10) Antimicrobial therapy: one o f the
following:
1) Oxytetracycline (5 mg/kgBW IM for 5-7
days).
2) Long acting tetracyclines at 10 mg/kg.
3) SC enrofloxacin (5 mg/kg)
4) Procaine penicillin 4000 IU/kg daily IM for
5-7 days.
5) Sulfonamides 200 mg/Kg for 5-7 days.
6) Combination of oxytetracycline and
sulfonamides.
7) Combination of tetracycline and penicillin.
23. (11) Anti-inflammatory therapy : one of the
following:
1) Corticosteroids and antihistamines, such as
dexamethasone 5-25 mg given I/M or I/V.
2) Non Steroidal anti-inflammatory drugs
(NSAIDs) such as acetyl salycilic acid (asprin)
(100 mg/kg every m hours) or flunixen
meglumine (2 mg/kg) either a single dose or
divided into two doses at 12 hour intervals.
NB: Care should be taken from renal toxicity,
so dehydrated animals should be rehydrated
before administration of these drugs.
24. NB: Avoid over dose or use them for prolonged
period because they may result in abomasal
ulceration.
(12) Heart tonic: one of the following:
1) Cardiazole 1-2 gm for horse according to
size.
2) Pulve digitalis. 1-4 gm for large animal. 1 /
2-4 gm for small animal. This dose must be
divided in 3 parts and given 3 times in three
days.
3) Repherin or pholiderin or adcopherine (IM),
5-10 c.c for large animal, 1 / 2-1 c.c. for small
animal.
25. * No treatment for interstitial pneumonia and the
diseased cattle should be slaughtered.
•
*MB: There is no specific treatment for the viral
pneumonias while mycoplasma spp. are sensitive to
antibiotics in vitro.
So, the pneumonias caused by them don’t respond to
treatment. This may be due to the intercellular location o
f the mycoplasma making them inaccessible to the
drugs.
Because, viral and mycoplasma pneumonias are
commonly complicated by secondary bacterial
infections, it is common practice to treat them with
antibiotics until recovery.
* Corticosteroids as anti-inflammatory effect in the
treatment o f acute pneumonia.
26. Prevention and control:
(1) Vaccination o f healthy dams.
(2) Good colostrum management, to give
adequate passive transfer.
(3) Disinfection o f calves’ navels to limit
pathogen exposure by over crowding and
direct contact.
(4) Provide a good-quality air and protects
the calf from bad environment.
(5) Avoid exposure of newborn to cold or
current air.
27. (6) Calves should be fed proper nutrition
for protein, energy, minerals and vitamins.
(7) Vaccination programs in dairy calves
should be start at 1-2 months o f age.
(8) Avoid over crowding and long
transportation in bad weather.
(9) Mass medication can be used to control
outbreaks of pneumonia in flocks.
Sulfonamides are administered in the
drinking water or orally at 200 mg/kg on the
first day and 66 mg/kg each subsequent day
of treatment.